Moleculin Biotech, Inc. (MBRX) — Institutional Holders, Q2 2026
18 institutional investment managers reported a MBRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $518.5K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
MBRX in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- VANGUARD CAPITAL MANAGEMENTAdded · +28,346 sh+$79.1K
- VANGUARD FIDUCIARYAdded · +23,811 sh+$66.4K
- XTX Topco LtdNew · +22,942 sh+$64.0K
- MORGAN STANLEYNew · +20,036 sh+$55.9K
- GEODE CAPITAL MANAGEMENTAdded · +14,923 sh+$41.6K
Biggest sellers
- SABBY MANAGEMENTSold out · -75,021 sh-$209.3K
- HRT FINANCIALSold out · -13,739 sh-$38.3K
- UBS Group AGSold out · -3,409 sh-$9.5K
- Pinnacle Wealth Planning ServicesSold out · -281 sh-$784.00
- Vanguard Global AdvisersSold out · -24 sh-$67.00
MBRX 13F holders ranked 1–18 of 18
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT#1 · 47,252 sh | 47,252 | $131.8K | 0.00% | +46.2% |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 42,215 sh | 42,215 | $117.8K | 0.00% | +204.4% |
| 3 | VANGUARD FIDUCIARY#3 · 29,883 sh | 29,883 | $83.4K | 0.00% | +392.1% |
| 4 | XTX Topco Ltd#4 · 22,942 sh | 22,942 | $64.0K | <0.01% | New |
| 5 | MORGAN STANLEY#5 · 20,036 sh | 20,036 | $55.9K | 0.00% | New |
| 6 | Rockefeller Capital Management L.P.#6 · 15,000 sh | 15,000 | $41.9K | <0.01% | +239.3% |
| 7 | Tower Research Capital (TRC)#7 · 3,514 sh | 3,514 | $9.8K | <0.01% | +91.5% |
| 8 | CITIGROUP#8 · 2,674 sh | 2,674 | $7.5K | 0.00% | New |
| 9 | BARCLAYS PLC#9 · 621 sh | 621 | $1.7K | 0.00% | New |
| 10 | BlackRock#10 · 491 sh | 491 | $1.4K | 0.00% | 0.0% |
| 11 | EFG International AG#11 · 434 sh | 434 | $1.2K | 0.00% | 0.0% |
| 12 | JONES FINANCIAL COMPANIES LLLP#12 · 360 sh | 360 | $1.2K | 0.00% | New |
| 13 | WELLS FARGO & COMPANY#13 · 200 sh | 200 | $558.00 | 0.00% | New |
| 14 | Newbridge Financial Services Group#14 · 114 sh | 114 | $318.00 | — | 0.0% |
| 15 | SBI Securities , Ltd.#15 · 44 sh | 44 | $123.00 | — | +2.3% |
| 16 | DANSKE BANK A/S#16 · 2 sh | 2 | $6.00 | 0.00% | 0.0% |
| 17 | CVA Family Office#17 · 1 sh | 1 | $3.00 | 0.00% | 0.0% |
| 18 | OSAIC#18 · 1 sh | 1 | $2.00 | 0.00% | 0.0% |
Funds that sold out of MBRX in Q2 2026 (7)
Held MBRX at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| SABBY MANAGEMENT75,021 sh | 75,021 | $171.8K |
| HRT FINANCIAL13,739 sh | 13,739 | $31.0K |
| UBS Group AG3,409 sh | 3,409 | $7.8K |
| Pinnacle Wealth Planning Services281 sh | 281 | $643.00 |
| Vanguard Global Advisers24 sh | 24 | $55.00 |
| FMR3 sh | 3 | $7.00 |
| Caitong International Asset Management , Ltd2 sh | 2 | $5.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.